Finn Ole Larsen

Medicine & Life Sciences

1. Oxaliplatin 100%
2. Colorectal Neoplasms 93%
3. Capecitabine 88%
4. Biliary Tract Neoplasms 81%
5. Rectal Neoplasms 53%
6. Irinotecan 50%
7. Neoplasm Metastasis 41%
8. Cetuximab 39%
9. Bevacizumab 31%
10. Survival 29%
11. gemcitabine 26%
12. Progression-Free Survival 24%
13. Therapeutics 23%
14. Safety 23%
15. Fluorouracil 21%
16. Neoplasms 21%
17. Cell-Free Nucleic Acids 20%
18. Liver 19%
19. Systematic Reviews 18%
20. Drug Therapy 17%
21. Induction Chemotherapy 16%
22. Biomarkers 15%
23. Radiotherapy 15%
24. Chemoradiotherapy 15%
25. Mutation 13%
26. XELOX 13%
27. Neoadjuvant Therapy 12%
28. Electrochemotherapy 12%
29. Randomized Controlled Trials 12%
30. regorafenib 12%
31. Mesalamine 10%
32. Exercise 10%
33. Procalcitonin 10%
34. Breast Neoplasms 10%
35. Delayed-Action Preparations 9%
36. Exome 9%
37. Electroporation 9%
38. Salvage Therapy 9%
39. Cisplatin 9%
40. Patient Participation 9%
41. Cardiotoxicity 9%
42. flt3 ligand protein 9%
43. Incidence 8%
44. Treatment Failure 8%
45. Colonic Neoplasms 8%
46. C-Reactive Protein 8%
47. Tumor Biomarkers 7%
48. Counseling 7%
49. Confidence Intervals 7%
50. Intravenous Administration 7%